Clearside Biomedical (CLSD) Tops Q2 EPS by 3c

Clearside Biomedical (NASDAQ: CLSD) reported Q2 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $90 thousand versus the consensus estimate of $151.8 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• Chevron reaches deal for two fields in Venezuela's Orinoco belt
• H.C. Wainwright Reiterates Buy Rating on Dogwood Therapeutics, Inc. (DWTX)
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance